This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
11/5/2026
Thank you for standing by. My name is Van and I will be your conference operator for today. At this time, I would like to welcome everyone to the LifeStance Health, Inc., LifeStance Health Third Quarter 2026 Earnings Call. All lines have been placed on mute to prevent any background noise. And after the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star 1 again. Thank you. I would now like to turn the call over to Monica Prokocki, VP of Finance and Investors Relations. Please go ahead.
Thank you, Operator. Good morning, everyone, and welcome to LifeStance Health's third quarter 2026 earnings conference call. I'm Monica Prokocki, Vice President of Finance and Investor Relations. Joining me today are Dave Bourdon, Chief Executive Officer, and Ryan McGroarty, Chief Financial Officer. We issued the earnings release and presentation before the market opened this morning. Both are available on the Investor Relations section of our website, investor.lifestance.com. In addition, a replay will be available following the call. Before turning over to management for their prepared remarks, Please direct your attention to the disclaimers about forward-looking statements included in the earnings press release and SEC filings. Today's remarks contain forward-looking statements, including statements about our financial performance outlook, business model, and strategy. Those statements involve risks, uncertainties, and other factors, as noted in our periodic filings with the SEC, that could cause actual results to differ materially. Please note that we report results using non-GAAP financial measures, which we believe provide additional information for investors to help facilitate comparison of current and past performance. A reconciliation to the most directly comparable GAAP measures is included in the earnings press release table and presentation appendix. Unless otherwise noted, all results are compared to the comparable period in the prior year. At this time, I'll turn the call over to Dave Bourdon, CEO of LifeStance. Dave?
Thanks, Monica, and thank you all for joining us today. This was a tremendous quarter for LifeStance, with momentum across all areas of the business. For the second consecutive quarter, we had revenue growth of 25% or more and adjusted EBITDA margins of 15%. We are once again raising our full-year guidance across all metrics, reflecting our confidence in the trajectory of the business. Ryan will provide additional detail on our updated outlook shortly. We continue to make great progress in increasing access to high-quality, affordable mental health care, growing our clinician base to more than 8,800 as the value proposition continues to resonate. Clinician productivity also remains very strong. building on last year's improvements and underscoring the strength and the scalability of LifeStance's model. Turning to technology, we continue to deploy digital tools, AI capabilities, and workflow automation to improve patient access, enhance the clinician experience, and drive greater efficiency across the organization. Regarding the EHR, We are making progress in preparing for the transition to the new vendor, which will occur throughout next year. We are advancing readiness efforts through workflow improvement and change management planning, positioning us for a successful phased rollout while minimizing disruption to clinicians and patients. In regards to geographic expansion, We remain excited about the significant opportunity to increase density in existing markets while also expanding into new geographies. Puckin acquisitions remain our preferred approach for entering new geographies, supported by a strong pipeline of opportunities. During the third quarter, we completed one tuck-in acquisition, which expanded our physical footprint into the state of Iowa. In addition, we are leveraging our proven de novo model to enter new markets and increase density in existing markets with the opening of eight new centers in the quarter and 20 year-to-date. I'd also like to provide an update on our clinical excellence journey. Delivering high quality care and improving patient outcomes remains central to our mission and is a key differentiator for LifeStance. We recently published new outcomes data highlighting the positive impact of our growing specialty services offering for patients with treatment-resistant depression. As a reminder, These are some of the highest acuity patients we serve as they have not responded successfully to other treatments before receiving TMS or Spravato. For Spravato, 74% of the patients experienced a clinically meaningful reduction in depression severity after 12 weeks of treatment. And for TMS, 61% experienced a clinically meaningful reduction Thank you for joining us. We added TMS at five additional sites and Spravato at four, bringing our total footprint to 37 centers offering TMS and 25 with Spravato. We will remain disciplined in the rollout of these services to meet patient demand while maintaining a high standard of clinical care. This has been an exceptional year for LifeStance, and I am incredibly proud of what our team has accomplished. As we strengthen the core business, expand capabilities and extend patient reach, we believe we are better positioned than ever to deliver excellent care at scale and create sustainable long-term value. The momentum we are seeing across the business reinforces our conviction in the strategy and the significant opportunity ahead. With that, I'll turn it over to Ryan to provide additional commentary on our financial performance and outlook. Ryan.
You're reading a preview of the LFST Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing